{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'other countries can replace the missing patients until completing the pre-specified sample', 'size.', '12.3', 'Variables', '12.3.1 Variables measured at the initial phase', 'At the initial phase the following data from the medical record will be collected:', 'Name of variable', 'Type of variable', 'Scale of', 'Categorization', 'measurement', 'Date of birth', 'Quantitative', 'Nominal', 'Residence country', 'Qualitative', 'Nominal', 'Colombia', 'Ecuador', 'Per\u00fa', 'Gender', 'Qualitative', 'Dichotomous', 'Female', 'Male', 'Ethnicity', 'Qualitative', 'Nominal', 'African American / Black', 'White / Caucasian', 'Hispanic/ Latin American', 'CONI', 'Current treatment', 'Qualitative', 'Nominal', 'EN', 'Indigenous', 'Methotrexate', 'Leflunomide', 'Tofacitinib', '#AL', 'Adalimumab', 'Etanercept', 'Certolizumab', 'Infliximab', 'Golimumab', 'Tocilizumab', 'Abatacept', 'Rituximab', 'Prednisolone', 'Deflazacort', 'NSAIDs', 'Years elapsed since the', 'Quantitative', 'disease was diagnosed', 'Prior anti-rheumatic', 'Qualitative', 'Nominal', 'Methotrexate', 'treatment', 'Leflunomide', 'Prednisolone', 'Sulfasalazine', 'Deflazacort', 'Hydroxychloroquine', 'Duration of prior treatments', 'Quantitative', '(months)', 'DAS28 score before the', 'Quantitative', 'Ordinal', 'Page 25 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'initiation of the evaluated', 'treatment', 'HAQ-DI score before the', 'Quantitative', 'Ordinal', 'initiation of the treatment to', 'evaluate', 'Erosion score before the', 'Quantitative', 'Ordinal', 'initiation of the evaluated', 'treatment', 'Number of tender joints', 'Quantitative', 'Ordinal', 'before the initiation of the', 'treatment to evaluate', 'Number of swollen joints', 'Quantitative', 'Ordinal', 'before the initiation of the', 'evaluated treatment', 'Lymphocytes count before', 'Quantitative', 'Ordinal', 'the initiation of the evaluated', 'treatment', 'Neutrophils count before the', 'Quantitative', 'Ordinal', 'initiation of the evaluated', 'treatment', 'Comorbidities (Non-', 'Qualitative', 'Nominal', 'Myocardial infarction', 'exhaustive) (Charlson score)', 'Cardiac failure', 'CONFIL', 'congestive', 'Peripheral disease', 'Stroke', 'Dementia', 'Chronic lung disease', 'Connective Tissue', 'Disease', 'Peptic Ulcer Disease', 'Mild hepatic disease', 'Diabetes without organ', 'damage', 'Hemiplegia', 'Severe or moderate', 'kidney disease', 'Diabetes with organ', 'damage.', 'Tumor without', 'metastasis', 'Leukemia', 'Lymphoma', 'Severe liver disease', 'Metastatic solid tumor', 'HIV', 'Page 26 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'The completeness of the information collected will depend on the quality of medical', 'records. In order to ensure the entirety of the information to record, the investigator', 'physician will collect the data related to the clinical variables based on source documents', 'and will be verified by the monitor.', '12.3.2 Effectiveness variables', 'Outcomes that will be assessed at day 1, and 6 months (approximately day 180) follow-up', 'are described below:', 'Functional status: it will be evaluated through the Health Assessment Questionnaire -', 'Disability Index (HAQ-DI) adapted since the 8 questions included in the RAPID', 'Questionnaire will not be included in this questionnaire section in CRF (Annex 2), the', \"disability assessment component of the HAQ, that assesses a patient's level of\", 'functional ability and includes questions of fine movements of the upper extremity,', 'locomotors activities of the lower extremity, and activities that involve both upper and', 'lower extremities(20,21), which consists of 8 categories: dressing, arising, eating,', 'walking, hygiene, reach, grip, reaching and common daily activities. Each category', 'consists of 2-3 items. Each item evaluates the functional status using the same', 'equipment the patient used the week before the questionnaire. Functional status levels', 'go from zero (0) to three (3), being zero (0) without any difficulty, one (1) with some', 'difficulty, two (2) with much difficulty and three (3) unable to do. In case of requiring', 'assistance from other person or device the patient must select a score of two (2). The', 'questionnaire HAQ-DI has been validated in Spanish by diverse Spanish-speaking', 'populations (22) and by Argentina (23) and must be completed entirely by the patient.', 'Quality of life: it will be evaluated through the Health Assessment Questionnaire EQ-', '5D (Annex 3), a standardized instrument for use as a measure of health outcome that', 'consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and', 'anxiety/depression. The scoring range goes from zero (0) to one hundred (100), being', 'one hundred the best quality of life (24). Official Spanish versions of EQ-5D-3L are', 'available at EuroQol webpage and must be licensed for this study (25). The', 'questionnaire must be completed by the patient.', 'Work productivity: it will be assessed through the Work Productivity and Activity', 'Impairment Questionnaire for Rheumatoid Arthritis (WPAI-AR) (Annex 4), that was', 'created as a Patient-Reported quantitative assessment of the amount of absenteeism,', 'presenteeism and daily activity impairment attributable to general health (WPAI:GH) or', 'a specific health problem (WPAI:SHP). The WPAI:GH and the WPAI:SHP were', 'created simultaneously and use the same template, but in the GH version the subject is', 'instructed to respond with reference to general health status while in the SHP version,', 'Page 27 of 64']\n\n###\n\n", "completion": "END"}